MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, SGP had $142,544K increase in cash & cash equivalents over the period. -$14,220K in free cash flow.

Cash Flow Overview

Change in Cash
$142,544K
Free Cash flow
-$14,220K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Gross proceeds from initial publ...
    • Redemptions of short-term invest...
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchases of short-term investme...
    • Payments for deferred initial pu...
    • Others

Cash Flow
2026-03-31
2025-12-31
Net loss
-13,818 -39,869
Depreciation expense
318 612
Loss on disposal of property and equipment
--5
Non-cash lease expense
63 383
Gain on lease termination
-518
Stock-based compensation
1,675 2,786
Change in fair value of redeemable convertible preferred stock tranche liability
0 1,526
Interest receivable
31 74
Other receivables
222 8
Prepaid expenses and other current assets
805 186
Other non-current assets
298 38
Accounts payable
953 549
Payroll-related accruals
-1,300 900
Accrued expenses and other current liabilities
-1,672
Other current liabilities
-104 -
Lease liability
25 -441
Net cash used in operating activities
-13,544 -32,701
Property and equipment
676 789
Purchases of short-term investments
4,000 17,001
Redemptions of short-term investments
3,009 5,996
Net cash used in investing activities
-1,667 -11,794
Proceeds from exercise of stock options
55 170
Repurchases of common stock
-1,450
Gross proceeds from issuance of redeemable convertible preferred stock
0 127,336
Issuance costs of redeemable convertible preferred stock
0 288
Gross proceeds from initial public offering of common stock, net of underwriting discounts and commissions
160,425 -
Payments for deferred initial public offering costs
2,725 1,183
Net cash provided by financing activities
157,755 124,585
Net increase in cash and cash equivalents
142,544 80,090
Cash and cash equivalents, beginning of period
96,358 16,268
Cash and cash equivalents, end of period
238,902 96,358
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Gross proceeds frominitial public offering...$160,425K Proceeds from exercise ofstock options$55K Net cash provided byfinancing activities$157,755K Canceled cashflow$2,725K Net increase in cashand cash...$142,544K Canceled cashflow$15,211K Payments for deferredinitial public offering...$2,725K Stock-based compensation$1,675K Accounts payable$953K Depreciation expense$318K Non-cash lease expense$63K Lease liability$25K Redemptions of short-terminvestments$3,009K Net cash used inoperating activities-$13,544K Net cash used ininvesting activities-$1,667K Canceled cashflow$3,034K Canceled cashflow$3,009K Net loss-$13,818K Purchases of short-terminvestments$4,000K Payroll-related accruals-$1,300K Prepaid expenses andother current assets$805K Other non-currentassets$298K Other receivables$222K Other currentliabilities-$104K Interest receivable$31K Property and equipment$676K

SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma, Inc. (SGP)